FDA 483 OBSERVATION · #296 OF 1,945 MOST-CITED

Component identity verification

FDA cited this observation 102 times across 98 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs102
BY FISCAL YEAR
FY202610
FY202511
FY202415
FY202313
FY20225
FY20212
FY20204
FY20198
FY201810
FY201716
FY20168

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.7× the rate of the average FDA-cited firm (44.9% vs 7.8%), across 98 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Natco Pharma Limited · Anakapalli · Drugs · 2026-08-21

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

CC Wellness, LLC · Valencia, California · Drugs · 2026-08-20

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Coastal Contract Packaging, Inc · Ventura, California · Drugs · 2026-08-11

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Cosmoceutical Research Center, Inc. · Panorama City, California · Drugs · 2026-05-29

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Westwood Laboratories, LLC. · Azusa, California · Drugs · 2026-03-26

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Dr. J Skinclinic, Inc · Cerritos, California · Drugs · 2026-03-23

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →